Long, G., & Hassel, J. C. (2016). PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis. Annals of oncology, 27, . https://doi.org/10.1093/annonc/mdw379.07
Chicago-Zitierstil (17. Ausg.)Long, Georgina, und Jessica C. Hassel. "PD-L1 Expression as a Biomarker for Nivolumab (NIVO) Plus Ipilimumab (IPI) and NIVO Alone in Advanced Melanoma (MEL): A Pooled Analysis." Annals of Oncology 27 (2016). https://doi.org/10.1093/annonc/mdw379.07.
MLA-Zitierstil (9. Ausg.)Long, Georgina, und Jessica C. Hassel. "PD-L1 Expression as a Biomarker for Nivolumab (NIVO) Plus Ipilimumab (IPI) and NIVO Alone in Advanced Melanoma (MEL): A Pooled Analysis." Annals of Oncology, vol. 27, 2016, https://doi.org/10.1093/annonc/mdw379.07.